08:07 AM EDT, 10/30/2024 (MT Newswires) -- Intra-Cellular Therapies ( ITCI ) reported a Q3 net loss Wednesday of $0.25 per diluted share, unchanged from a year earlier.
Analysts polled by Capital IQ expected a loss of $0.21.
Total revenue for the quarter ended Sept. 30 was $175.4 million, compared with $126.2 million a year earlier.
Analysts surveyed by Capital IQ expected $172.4 million.
Intra-Cellular shares were nearly 3% higher in premarket trading.